ReviewThe Medical clinics of North America2023
Updates in Cardiorenal Syndrome.
Review in The Medical clinics of North America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The Heart-Kidney Axis in Heart Failure and Chronic Kidney Disease: Mechanisms, Mediators, and Therapeutic Implications.Biomolecules · 2026Review
- Decoding cardiorenal crosstalk: Intercellular communication mechanisms and therapeutic insights in cardiorenal syndrome.iScience · 2026Review
- O-GlcNAcylation: A bridge for regulating the function of the "heart-kidney-bone axis".Biochemistry and biophysics reports · 2026Review
- Cardiorenal Syndrome Type 1 in Patients with Heart Failure with Preserved Ejection Fraction.Journal of clinical medicine · 2026Review
- A predictive model for the risk of death within 30 days in patients with cardiorenal syndrome treated with continuous renal replacement therapy: A retrospective study based on the MIMIC-IV database.Scientific reports · 2026Article
- Admission Renal Dysfunction Severity as a Prognostic Factor in Older Patients With Acute Heart Failure.Circulation reports · 2026Article
- Association between relative fat mass and chronic cardiorenal syndrome: A cross-sectional study based on NHANES 1999 to 2018.Medicine · 2026Article
- [63/m with progressive dyspnea, lower leg edema and oliguria : Preparation for the medical specialist examination: part 18].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026Article
- Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms.BioMed research international · 2026Review
- Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.Cardiovascular drugs and therapy · 2025Article
- Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i.Renal failure · 2025Review
- Review
- Association of longitudinal blood urea nitrogen trajectory with in-hospital and 28-day mortality in acute heart failure with cardiorenal syndrome.European journal of medical research · 2025Article
- Diuretic Use in Heart Failure.Reviews in cardiovascular medicine · 2025Review
- Cardiorenal Syndrome in the Elderly: Challenges and Considerations.Geriatrics (Basel, Switzerland) · 2025Review
- Prognostic value of dynamic KDIGO staging in acute kidney injury after acute heart failure: a doubly robust analysis.Scientific reports · 2025Article
- The association of albumin-corrected anion gap and acute kidney injury in heart failure patients: a competing risk model analysis.BMC cardiovascular disorders · 2025Article
- Current Perspectives on the NF-κB Signaling Axis as a Potential Pharmacological Target in Cardiorenal Syndrome.Drug design, development and therapy · 2025Review
- Acute kidney injury after myocardial infarction: prognostic implications via dual robust methods.Frontiers in medicine · 2025Article
- Ubiquitin-Specific Protease 18 in Chronic Kidney Disease-Another Emerging Biomarker to Consider?Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cardiorenal syndrome is a term that refers to a collection of disorders involving both the heart and kidneys, encompassing multi-directional pathways between the 2 organs mediated through low arterial perfusion, venous congestion, and neurohormonal activation. The pathophysiology is complex and includes hemodynamic and neurohormonal changes, but inconsistent findings from recent studies suggest this is very heterogenous disorder. Management for ADHF remains focused on decongestion and neurohormonal blockade to overcome the intense sodium and fluid avidity of the CRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.